Chronic spontaneous urticaria that is not controlled by a standard dose of a second-generation antihistamine often responds when the same drug is increased up to four times the licensed dose, which international urticaria guidelines recommend before a biologic. Patients frequently arrive having tried several different antihistamines at standard dose, or a sedating one at night, without ever having had an adequate trial of up-dosing.
Give each step a few weeks, use an activity or control score to judge response, and only then consider omalizumab.
- Use a single second-generation antihistamine and increase up to four times the standard dose if needed.
- Allow two to four weeks at each step before judging response.
- Avoid rotating between antihistamines at standard dose as a substitute for up-dosing.
- Measure control with a validated score so escalation decisions are documented.
Why it matters
Many referrals for biologics have never had an adequate antihistamine trial.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free